Cover Image
close this bookCote d'Ivoire Ministry of Health - UNAIDS HIV/AIDS Drug Access Initiative - Preliminary Report (UNAIDS, 2000, 22 p.)
View the document(introduction...)
View the documentIntroduction
View the documentObjectives - Program evaluation
close this folderProcedures - Methods
View the document(introduction...)
View the document1. Eligibility screening
View the document2. Initiation of therapy
View the document3. Follow-up
View the documentResults

1. Eligibility screening

A social worker in each of the accredited centers collects sociodemographic information upon presentation of each patient. Then, a physician assesses the patient's past medical history including prior and current ARV drug use, and a physical exam is performed. To determine biologic eligibility, a blood sample is then drawn. The specimen is sent to Projet RETRO-CI laboratory for serum chemistry, hematology, CD4 count and viral load. CD4 count was performed by flow cytometry (Facscan, Becton Dickinson, Aalst-Erembodegem, Belgium). HIV-1 RNA viral load was quantified in the plasma by reverse transcriptase PCR (RT-PCR) Amplicor HIV-1 Monitor Assay, version 1.5 (Roche Diagnostics Systems, Branchburg, NJ). This assay accurately quantifies HIV-1 subtype A/G recombinant viruses which are the predominant subtypes in Cd'Ivoire. The limit of viral detection was 200 copies/ml.

Upon request of the physician, Projet RETRO-CI submits a standardized anonymous summary report to the national committee for application and deliberation regarding the subsidy.